NCT07215936Active, not recruitingPhase 2
Dose-dense Capecitabine Schedule [7days on _7 Days Off] in Colorectal Cancer in Comparison With Standered Regimen
Dose_dense Capecitabine Schedule [7days on _7days Off] in Colorectal Cancer in Comparison With Standered Regimen
Source: ClinicalTrials.gov · Last updated 14 Oct 2025
Brief summary (registry, in English)
Dose\_dense Capecitabine Schedule in colorectal cancers
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 4 Oct 2025
- Start date
- 25 Sept 2025
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- Sohag University
- Diseases
- Colorectal cancer
- NCT number
- NCT07215936
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 100
- From 25 Sept 2025 to the primary completion date, 30 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- pateints with other malignancy Pateints who have other comorbid diseas
Who the study is looking for
- patients who diagnosed colorectal cancer Performance status ranging from 0 to 2 Both sexs
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sohag University Hospital Coordinator of this site? Confirm its status | Sohag | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.